Identification of risk variants related to malignant tumors in children with birth defects by whole genome sequencing.
Birth defect
Pediatric cancer
Whole genome sequencing
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
16 Nov 2022
16 Nov 2022
Historique:
received:
06
09
2022
accepted:
03
11
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Children with birth defects (BD) are more likely to develop cancer and the increased risk of cancer persists into adulthood. Prior population-based assessments have demonstrated that even non-chromosomal BDs are associated with at least two-fold increase of cancer risk. Identification of variants that are associated with malignant tumor in BD patients without chromosomal anomalies may improve our understanding of the underlying molecular mechanisms and provide clues for early cancer detection in children with BD. In this study, whole genome sequencing (WGS) data of blood-derived DNA for 1653 individuals without chromosomal anomalies were acquired from the Kids First Data Resource Center (DRC), including 541 BD probands with at least one type of malignant tumors, 767 BD probands without malignant tumor, and 345 healthy family members who are the parents or siblings of the probands. Recurrent variants exclusively seen in cancer patients were selected and mapped to their corresponding genomic regions. The targeted genes/non-coding RNAs were further reduced using random forest and forward feature selection (ffs) models. The filtered genes/non-coding RNAs, including variants in non-coding areas, showed enrichment in cancer-related pathways. To further support the validity of these variants, blood WGS data of additional 40 independent BD probands, including 25 patients with at least one type of cancers from unrelated projects, were acquired. The counts of variants of interest identified in the Kid First data showed clear deviation in the validation dataset between BD patients with cancer and without cancer. Furthermore, a deep learning model was built to assess the predictive abilities in the 40 patients using variants of interest identified in the Kids First cohort as feature vectors. The accuracies are ~ 75%, with the noteworthy observation that variants mapped to non-coding regions provided the highest accuracy (31 out of 40 patients were labeled correctly). We present for the first time a panorama of genetic variants that are associated with cancers in non-chromosomal BD patients, implying that our approach may potentially serve for the early detection of malignant tumors in patients with BD.
Sections du résumé
BACKGROUND
BACKGROUND
Children with birth defects (BD) are more likely to develop cancer and the increased risk of cancer persists into adulthood. Prior population-based assessments have demonstrated that even non-chromosomal BDs are associated with at least two-fold increase of cancer risk. Identification of variants that are associated with malignant tumor in BD patients without chromosomal anomalies may improve our understanding of the underlying molecular mechanisms and provide clues for early cancer detection in children with BD.
METHODS
METHODS
In this study, whole genome sequencing (WGS) data of blood-derived DNA for 1653 individuals without chromosomal anomalies were acquired from the Kids First Data Resource Center (DRC), including 541 BD probands with at least one type of malignant tumors, 767 BD probands without malignant tumor, and 345 healthy family members who are the parents or siblings of the probands. Recurrent variants exclusively seen in cancer patients were selected and mapped to their corresponding genomic regions. The targeted genes/non-coding RNAs were further reduced using random forest and forward feature selection (ffs) models.
RESULTS
RESULTS
The filtered genes/non-coding RNAs, including variants in non-coding areas, showed enrichment in cancer-related pathways. To further support the validity of these variants, blood WGS data of additional 40 independent BD probands, including 25 patients with at least one type of cancers from unrelated projects, were acquired. The counts of variants of interest identified in the Kid First data showed clear deviation in the validation dataset between BD patients with cancer and without cancer. Furthermore, a deep learning model was built to assess the predictive abilities in the 40 patients using variants of interest identified in the Kids First cohort as feature vectors. The accuracies are ~ 75%, with the noteworthy observation that variants mapped to non-coding regions provided the highest accuracy (31 out of 40 patients were labeled correctly).
CONCLUSION
CONCLUSIONS
We present for the first time a panorama of genetic variants that are associated with cancers in non-chromosomal BD patients, implying that our approach may potentially serve for the early detection of malignant tumors in patients with BD.
Identifiants
pubmed: 36384586
doi: 10.1186/s40364-022-00431-y
pii: 10.1186/s40364-022-00431-y
pmc: PMC9670520
doi:
Types de publication
Journal Article
Langues
eng
Pagination
84Informations de copyright
© 2022. The Author(s).
Références
Genomics. 2021 Jan;113(1 Pt 2):1141-1154
pubmed: 33189777
Oncoimmunology. 2016 Jan 13;5(4):e1119356
pubmed: 27141405
Trends Cancer. 2019 Aug;5(8):475-494
pubmed: 31421905
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Nat Genet. 2004 May;36(5):431-2
pubmed: 15118671
Circ Res. 2019 Feb 15;124(4):553-563
pubmed: 30582441
Postepy Hig Med Dosw (Online). 2013 Sep 10;67:950-7
pubmed: 24088538
J Transl Med. 2019 Apr 8;17(1):116
pubmed: 30961610
JAMA Oncol. 2019 Aug 01;5(8):1150-1158
pubmed: 31219523
World J Clin Oncol. 2018 Sep 14;9(5):74-82
pubmed: 30254962
J Neurosci. 2007 Jun 6;27(23):6333-47
pubmed: 17554007
J Exp Clin Cancer Res. 2022 Aug 11;41(1):242
pubmed: 35953818
J Craniomaxillofac Surg. 2016 Jan;44(1):16-20
pubmed: 26602496
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Cells. 2021 May 17;10(5):
pubmed: 34067762
BMJ. 2020 Dec 2;371:m4060
pubmed: 33268348
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486302
J Cell Mol Med. 2020 Sep;24(17):9705-9711
pubmed: 32697011
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Birth Defects Res C Embryo Today. 2003 Nov;69(4):305-17
pubmed: 14745971
Cancer Biol Med. 2017 Feb;14(1):90-99
pubmed: 28443208
Sci Rep. 2020 Feb 6;10(1):2022
pubmed: 32029803
J Pediatr Surg. 2001 Jun;36(6):885-7
pubmed: 11381418
PLoS One. 2015 Oct 30;10(10):e0141285
pubmed: 26517117
Cancers (Basel). 2020 Dec 10;12(12):
pubmed: 33321819
Cancers (Basel). 2021 Dec 10;13(24):
pubmed: 34944834
PLoS One. 2013 Jul 17;8(7):e69077
pubmed: 23874873
BMC Med Genomics. 2021 Nov 4;14(1):260
pubmed: 34736471
Nat Rev Cancer. 2005 Jul;5(7):505-15
pubmed: 16069815